
    
      The aim of NiQoLe, phase IV study is to evaluate tolerability of Niraparib and the management
      by the physicians of the side-effects in real life in France. The study will also generate
      complementary data of NOVA trial on longitudinal follow up of closed symptoms and side
      effects reported by the patients especially with the NCI PRO (Patient-Reported Outcome)-CTCAE
      system. Specific oncogeriatric data will be collected among on a subgroup of elderly
      patients.
    
  